STOCK TITAN

[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On June 30, 2025, Inhibikase Therapeutics, Inc. (IKT) filed a Form 4 reporting that Director Vincent Aurentz received a stock option covering 108,176 common shares at an exercise price of $1.95 per share. The option vests on the earlier of June 30, 2026 or the day prior to the next annual shareholders meeting, provided the director remains in service, and expires on June 30, 2032. After the grant, Mr. Aurentz beneficially owns 108,176 derivative securities and reported no transactions in directly held common stock. The transaction was coded “A” (acquisition), indicating a routine equity award under the company’s director compensation program, with no cash paid and no shares sold.

Il 30 giugno 2025, Inhibikase Therapeutics, Inc. (IKT) ha presentato un Modulo 4 segnalando che il Direttore Vincent Aurentz ha ricevuto un'opzione su azioni che copre 108.176 azioni ordinarie a un prezzo di esercizio di 1,95 $ per azione. L'opzione matura alla data più vicina tra il 30 giugno 2026 o il giorno precedente la prossima assemblea annuale degli azionisti, a condizione che il direttore rimanga in carica, e scade il 30 giugno 2032. Dopo la concessione, il Sig. Aurentz detiene beneficiariamente 108.176 titoli derivati e non ha riportato transazioni su azioni ordinarie detenute direttamente. L'operazione è stata classificata come “A” (acquisizione), indicando un premio azionario ordinario nell'ambito del programma di compensazione per i direttori della società, senza alcun pagamento in contanti né vendita di azioni.

El 30 de junio de 2025, Inhibikase Therapeutics, Inc. (IKT) presentó un Formulario 4 informando que el Director Vincent Aurentz recibió una opción sobre acciones que cubre 108,176 acciones ordinarias a un precio de ejercicio de $1.95 por acción. La opción se consolida en la fecha que ocurra primero entre el 30 de junio de 2026 o el día previo a la próxima junta anual de accionistas, siempre que el director continúe en servicio, y vence el 30 de junio de 2032. Tras la concesión, el Sr. Aurentz posee beneficiosamente 108,176 valores derivados y no reportó transacciones con acciones ordinarias en propiedad directa. La transacción fue codificada como “A” (adquisición), indicando una concesión rutinaria de acciones bajo el programa de compensación para directores de la empresa, sin pago en efectivo ni venta de acciones.

2025년 6월 30일, Inhibikase Therapeutics, Inc. (IKT)는 이사 Vincent Aurentz가 주당 $1.95의 행사가격으로 108,176 보통주에 대한 스톡옵션을 받았음을 보고하는 Form 4를 제출했습니다. 이 옵션은 이사가 계속 재직하는 조건 하에 2026년 6월 30일 또는 다음 연례 주주총회 전날 중 빠른 날짜에 취득되며, 2032년 6월 30일에 만료됩니다. 부여 후 Aurentz 씨는 108,176 파생증권을 실질적으로 소유하고 있으며 직접 보유한 보통주에 대한 거래는 보고하지 않았습니다. 이 거래는 “A”(취득) 코드로 처리되었으며, 회사 이사 보상 프로그램에 따른 정기 주식 보상으로 현금 지급이나 주식 매도 없이 이루어졌습니다.

Le 30 juin 2025, Inhibikase Therapeutics, Inc. (IKT) a déposé un formulaire 4 indiquant que le directeur Vincent Aurentz a reçu une option d'achat portant sur 108 176 actions ordinaires au prix d'exercice de 1,95 $ par action. L'option devient acquise à la date la plus proche entre le 30 juin 2026 ou la veille de la prochaine assemblée annuelle des actionnaires, à condition que le directeur reste en fonction, et expire le 30 juin 2032. Après l'attribution, M. Aurentz détient bénéficiairement 108 176 titres dérivés et n'a signalé aucune transaction sur des actions ordinaires détenues directement. La transaction a été codée « A » (acquisition), indiquant une attribution d'actions de routine dans le cadre du programme de rémunération des administrateurs de la société, sans paiement en espèces ni vente d'actions.

Am 30. Juni 2025 reichte Inhibikase Therapeutics, Inc. (IKT) ein Formular 4 ein, in dem berichtet wurde, dass Direktor Vincent Aurentz eine Aktienoption über 108.176 Stammaktien zu einem Ausübungspreis von 1,95 $ pro Aktie erhalten hat. Die Option wird entweder am 30. Juni 2026 oder am Tag vor der nächsten jährlichen Hauptversammlung der Aktionäre fällig, je nachdem, welcher Zeitpunkt früher liegt, vorausgesetzt, der Direktor bleibt im Amt, und läuft am 30. Juni 2032 ab. Nach der Gewährung besitzt Herr Aurentz wirtschaftlich 108.176 derivative Wertpapiere und meldete keine Transaktionen mit direkt gehaltenen Stammaktien. Die Transaktion wurde mit „A“ (Erwerb) codiert, was auf eine routinemäßige Aktienzuteilung im Rahmen des Vergütungsprogramms für Direktoren des Unternehmens hinweist, ohne Barauszahlung oder Aktienverkauf.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director option grant; neutral investor impact.

The filing discloses a single Type “A” acquisition: 108,176 stock options awarded to Director Vincent Aurentz at a $1.95 strike. Vesting is service-based through June 2026 with expiration in June 2032. No common-share sales or other derivative trades are reported. This aligns with typical board compensation practices and neither alters control dynamics nor signals a change in insider sentiment. Governance and financial impacts are therefore neutral.

TL;DR: No immediate earnings or cash impact; neutral event.

The option grant involves no current cash expense for the company and does not affect the share count until potential future exercise at $1.95. The absence of share disposals removes negative signaling risk. Consequently, the event is not expected to influence portfolio positioning or valuation models.

Il 30 giugno 2025, Inhibikase Therapeutics, Inc. (IKT) ha presentato un Modulo 4 segnalando che il Direttore Vincent Aurentz ha ricevuto un'opzione su azioni che copre 108.176 azioni ordinarie a un prezzo di esercizio di 1,95 $ per azione. L'opzione matura alla data più vicina tra il 30 giugno 2026 o il giorno precedente la prossima assemblea annuale degli azionisti, a condizione che il direttore rimanga in carica, e scade il 30 giugno 2032. Dopo la concessione, il Sig. Aurentz detiene beneficiariamente 108.176 titoli derivati e non ha riportato transazioni su azioni ordinarie detenute direttamente. L'operazione è stata classificata come “A” (acquisizione), indicando un premio azionario ordinario nell'ambito del programma di compensazione per i direttori della società, senza alcun pagamento in contanti né vendita di azioni.

El 30 de junio de 2025, Inhibikase Therapeutics, Inc. (IKT) presentó un Formulario 4 informando que el Director Vincent Aurentz recibió una opción sobre acciones que cubre 108,176 acciones ordinarias a un precio de ejercicio de $1.95 por acción. La opción se consolida en la fecha que ocurra primero entre el 30 de junio de 2026 o el día previo a la próxima junta anual de accionistas, siempre que el director continúe en servicio, y vence el 30 de junio de 2032. Tras la concesión, el Sr. Aurentz posee beneficiosamente 108,176 valores derivados y no reportó transacciones con acciones ordinarias en propiedad directa. La transacción fue codificada como “A” (adquisición), indicando una concesión rutinaria de acciones bajo el programa de compensación para directores de la empresa, sin pago en efectivo ni venta de acciones.

2025년 6월 30일, Inhibikase Therapeutics, Inc. (IKT)는 이사 Vincent Aurentz가 주당 $1.95의 행사가격으로 108,176 보통주에 대한 스톡옵션을 받았음을 보고하는 Form 4를 제출했습니다. 이 옵션은 이사가 계속 재직하는 조건 하에 2026년 6월 30일 또는 다음 연례 주주총회 전날 중 빠른 날짜에 취득되며, 2032년 6월 30일에 만료됩니다. 부여 후 Aurentz 씨는 108,176 파생증권을 실질적으로 소유하고 있으며 직접 보유한 보통주에 대한 거래는 보고하지 않았습니다. 이 거래는 “A”(취득) 코드로 처리되었으며, 회사 이사 보상 프로그램에 따른 정기 주식 보상으로 현금 지급이나 주식 매도 없이 이루어졌습니다.

Le 30 juin 2025, Inhibikase Therapeutics, Inc. (IKT) a déposé un formulaire 4 indiquant que le directeur Vincent Aurentz a reçu une option d'achat portant sur 108 176 actions ordinaires au prix d'exercice de 1,95 $ par action. L'option devient acquise à la date la plus proche entre le 30 juin 2026 ou la veille de la prochaine assemblée annuelle des actionnaires, à condition que le directeur reste en fonction, et expire le 30 juin 2032. Après l'attribution, M. Aurentz détient bénéficiairement 108 176 titres dérivés et n'a signalé aucune transaction sur des actions ordinaires détenues directement. La transaction a été codée « A » (acquisition), indiquant une attribution d'actions de routine dans le cadre du programme de rémunération des administrateurs de la société, sans paiement en espèces ni vente d'actions.

Am 30. Juni 2025 reichte Inhibikase Therapeutics, Inc. (IKT) ein Formular 4 ein, in dem berichtet wurde, dass Direktor Vincent Aurentz eine Aktienoption über 108.176 Stammaktien zu einem Ausübungspreis von 1,95 $ pro Aktie erhalten hat. Die Option wird entweder am 30. Juni 2026 oder am Tag vor der nächsten jährlichen Hauptversammlung der Aktionäre fällig, je nachdem, welcher Zeitpunkt früher liegt, vorausgesetzt, der Direktor bleibt im Amt, und läuft am 30. Juni 2032 ab. Nach der Gewährung besitzt Herr Aurentz wirtschaftlich 108.176 derivative Wertpapiere und meldete keine Transaktionen mit direkt gehaltenen Stammaktien. Die Transaktion wurde mit „A“ (Erwerb) codiert, was auf eine routinemäßige Aktienzuteilung im Rahmen des Vergütungsprogramms für Direktoren des Unternehmens hinweist, ohne Barauszahlung oder Aktienverkauf.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aurentz Vincent

(Last) (First) (Middle)
1000 N. WEST STREET, SUITE 1200

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.95 06/30/2025 A 108,176 (1) 06/30/2032 Common Stock 108,176 $0 108,176 D
Explanation of Responses:
1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ David McIntyre, attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What size stock option grant did Director Vincent Aurentz receive from Inhibikase (IKT)?

He received 108,176 stock options.

What is the exercise price of the options granted to the IKT director?

The options carry an exercise price of $1.95 per share.

When do the options awarded on 06/30/2025 vest?

They vest on the earlier of June 30, 2026 or the day before the next annual shareholders meeting, contingent on continued service.

What is the expiration date of these director options?

The options expire on June 30, 2032.

Did the Form 4 report any sale of Inhibikase Therapeutics shares?

No, the filing indicates no sale of common shares.

How many derivative securities does the director own after the transaction?

Mr. Aurentz beneficially owns 108,176 derivative securities following the grant.
Inhibikase Therapeutics Inc

NASDAQ:IKT

IKT Rankings

IKT Latest News

IKT Latest SEC Filings

IKT Stock Data

122.66M
58.74M
12.35%
76.05%
1.89%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
ATLANTA